[
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings Call Highlights: Strong Growth and Strategic ...",
    "summary": "Bristol-Myers Squibb Co (BMY) reports robust revenue growth and strategic milestones, raising full-year guidance amid competitive challenges.",
    "url": "https://finnhub.io/api/news?id=c1f0fd688dbe3d6e49f9ea6079ff0249d11183c63ba9daab91e9a163c28b74ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761855865,
      "headline": "Bristol-Myers Squibb Co (BMY) Q3 2025 Earnings Call Highlights: Strong Growth and Strategic ...",
      "id": 137275176,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Co (BMY) reports robust revenue growth and strategic milestones, raising full-year guidance amid competitive challenges.",
      "url": "https://finnhub.io/api/news?id=c1f0fd688dbe3d6e49f9ea6079ff0249d11183c63ba9daab91e9a163c28b74ff"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (BMY) Stock Trades Up, Here Is Why",
    "summary": "Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 4.3% in the morning session after the company posted third-quarter financial results that beat expectations and raised its full-year sales forecast. Total revenues for the quarter came in at $12.22 billion, an increase of 2.8% from the same period a year ago, surpassing analyst estimates. The company also reported adjusted earnings of $1.63 per share, which was better than anticipated. Following these results, Bristol-Mye",
    "url": "https://finnhub.io/api/news?id=c61a1ae0dbd5de88d5ff8608f74a5694ab067d520f7887f738afa6c3ae02dc37",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761852979,
      "headline": "Bristol-Myers Squibb (BMY) Stock Trades Up, Here Is Why",
      "id": 137269277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 4.3% in the morning session after the company posted third-quarter financial results that beat expectations and raised its full-year sales forecast. Total revenues for the quarter came in at $12.22 billion, an increase of 2.8% from the same period a year ago, surpassing analyst estimates. The company also reported adjusted earnings of $1.63 per share, which was better than anticipated. Following these results, Bristol-Mye",
      "url": "https://finnhub.io/api/news?id=c61a1ae0dbd5de88d5ff8608f74a5694ab067d520f7887f738afa6c3ae02dc37"
    }
  },
  {
    "ts": null,
    "headline": "Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson",
    "summary": "Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The \"Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan",
    "url": "https://finnhub.io/api/news?id=9a0326b70bd21d4034bf6fd8947f86a65c4eb02d4b5a41850de931e9a4df3c99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761844560,
      "headline": "Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson",
      "id": 137268736,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The \"Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan",
      "url": "https://finnhub.io/api/news?id=9a0326b70bd21d4034bf6fd8947f86a65c4eb02d4b5a41850de931e9a4df3c99"
    }
  },
  {
    "ts": null,
    "headline": "Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win",
    "summary": "Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called “lackluster” appeal and Bristol Myers’ prized schizophrenia drug again underwhelmed.",
    "url": "https://finnhub.io/api/news?id=0b7db40fdb24f96cfc1522576d238ff69d113c1cd783728c9e61141b9c70cde9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761844380,
      "headline": "Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win",
      "id": 137275177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Alnylam and Neurocrine shares tumbled despite upbeat sales reports. Elsewhere, Biogen is dealing with what one analyst called “lackluster” appeal and Bristol Myers’ prized schizophrenia drug again underwhelmed.",
      "url": "https://finnhub.io/api/news?id=0b7db40fdb24f96cfc1522576d238ff69d113c1cd783728c9e61141b9c70cde9"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera",
    "summary": "The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed obesity-drug developer.",
    "url": "https://finnhub.io/api/news?id=d9b84b939e3ac2967d6030ae77894e1eebd820733f2cd595bc141e66cca64fce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761821760,
      "headline": "Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera",
      "id": 137266702,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed obesity-drug developer.",
      "url": "https://finnhub.io/api/news?id=d9b84b939e3ac2967d6030ae77894e1eebd820733f2cd595bc141e66cca64fce"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript",
    "summary": "Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDTCompany ParticipantsChuck TrianoChristopher Boerner - CEO &...",
    "url": "https://finnhub.io/api/news?id=8d92a71b684464f99e2fb6dffbd20af5019b97ca5ace97ba7ed1d89d3ba18e7b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761840400,
      "headline": "Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript",
      "id": 137269347,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDTCompany ParticipantsChuck TrianoChristopher Boerner - CEO &...",
      "url": "https://finnhub.io/api/news?id=8d92a71b684464f99e2fb6dffbd20af5019b97ca5ace97ba7ed1d89d3ba18e7b"
    }
  },
  {
    "ts": null,
    "headline": "Estée Lauder's turnaround plan, Mastercard beats Q3 estimates",
    "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Estée Lauder (EL) beating profit estimates amid its brand turnaround plan, Mastercard (MA) topping third quarter expectations on its top and bottom lines, and Bristol-Myers Squibb (BMY) raising its revenue outlook. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=f35a5258af5c1953348b97ae9c01e5266f8745a6f35ef43887bede086a58ac25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761835252,
      "headline": "Estée Lauder's turnaround plan, Mastercard beats Q3 estimates",
      "id": 137268716,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Estée Lauder (EL) beating profit estimates amid its brand turnaround plan, Mastercard (MA) topping third quarter expectations on its top and bottom lines, and Bristol-Myers Squibb (BMY) raising its revenue outlook. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=f35a5258af5c1953348b97ae9c01e5266f8745a6f35ef43887bede086a58ac25"
    }
  },
  {
    "ts": null,
    "headline": "BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View",
    "summary": "Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.",
    "url": "https://finnhub.io/api/news?id=5f1b0621ed88adc084f8b32cded96f37cc3256b1b726975b10c2abcc7f7cb852",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761834720,
      "headline": "BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View",
      "id": 137268891,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.",
      "url": "https://finnhub.io/api/news?id=5f1b0621ed88adc084f8b32cded96f37cc3256b1b726975b10c2abcc7f7cb852"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain",
    "summary": "Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.",
    "url": "https://finnhub.io/api/news?id=2d2281d2aeeb41d23785308c25ba1f8b1e19a992391020c245ed5672aecfeb81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761831826,
      "headline": "Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain",
      "id": 137266602,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.",
      "url": "https://finnhub.io/api/news?id=2d2281d2aeeb41d23785308c25ba1f8b1e19a992391020c245ed5672aecfeb81"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers (BMY) Reports Q3 Earnings: What Key Metrics Have to Say",
    "summary": "The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=0dbd4b5442d1e081eebb155c46353347ef118ba3cf6a516d0a9bc058d4eb26bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761831004,
      "headline": "Bristol Myers (BMY) Reports Q3 Earnings: What Key Metrics Have to Say",
      "id": 137269282,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=0dbd4b5442d1e081eebb155c46353347ef118ba3cf6a516d0a9bc058d4eb26bb"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead",
    "summary": "Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead",
    "url": "https://finnhub.io/api/news?id=cb1b8f4c7c7ce4702477df3b39e2ff4667a47fef64a63b5077548bb8f0313542",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761830577,
      "headline": "Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead",
      "id": 137268194,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=cb1b8f4c7c7ce4702477df3b39e2ff4667a47fef64a63b5077548bb8f0313542"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q3",
    "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year revenue guidance of $47.75 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 7.6% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=71ed78f56e6b5f085890b1b22ac34348fa5d22e5bfd8a8fc724c796c2ac5d793",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761830494,
      "headline": "Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q3",
      "id": 137266779,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 2.8% year on year to $12.22 billion. The company’s full-year revenue guidance of $47.75 billion at the midpoint came in 0.9% above analysts’ estimates. Its non-GAAP profit of $1.63 per share was 7.6% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=71ed78f56e6b5f085890b1b22ac34348fa5d22e5bfd8a8fc724c796c2ac5d793"
    }
  },
  {
    "ts": null,
    "headline": "United States Vitiligo Market Research Report 2025-2033 by Diseases Type, Treatment Type, End User, Regions and Company Analysis",
    "summary": "The United States vitiligo market is projected to grow from $202.87 million in 2024 to $320.71 million by 2033, driven by a 5.22% CAGR from 2025. This growth is fueled by increasing awareness, innovative therapies, and improved diagnostic methods. Key treatment advancements include biologics, phototherapy, and topical solutions. Challenges include limited curative options and high treatment costs. States like California, New York, Texas, and Florida lead due to strong healthcare infrastructure.",
    "url": "https://finnhub.io/api/news?id=60dd52abbf66ab4c4edcebd2fa5e1fcb4c42d42107d0218c3e0a9d508068aa11",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761829080,
      "headline": "United States Vitiligo Market Research Report 2025-2033 by Diseases Type, Treatment Type, End User, Regions and Company Analysis",
      "id": 137266780,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The United States vitiligo market is projected to grow from $202.87 million in 2024 to $320.71 million by 2033, driven by a 5.22% CAGR from 2025. This growth is fueled by increasing awareness, innovative therapies, and improved diagnostic methods. Key treatment advancements include biologics, phototherapy, and topical solutions. Challenges include limited curative options and high treatment costs. States like California, New York, Texas, and Florida lead due to strong healthcare infrastructure.",
      "url": "https://finnhub.io/api/news?id=60dd52abbf66ab4c4edcebd2fa5e1fcb4c42d42107d0218c3e0a9d508068aa11"
    }
  },
  {
    "ts": null,
    "headline": "Are Wall Street Analysts Predicting Bristol-Myers Squibb Stock Will Climb or Sink?",
    "summary": "Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=0215ec2562f5024bd18d1c73c811034f677eec99c648a2af58e962e375b33696",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761827278,
      "headline": "Are Wall Street Analysts Predicting Bristol-Myers Squibb Stock Will Climb or Sink?",
      "id": 137269283,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=0215ec2562f5024bd18d1c73c811034f677eec99c648a2af58e962e375b33696"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates",
    "summary": "Bristol Myers (BMY) delivered earnings and revenue surprises of +10.14% and +3.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=622fd2c997dcc3e91196a3e661182616f1e1c5b485cb1ce6b6aaaf14463bb431",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761826202,
      "headline": "Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Surpass Estimates",
      "id": 137266781,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers (BMY) delivered earnings and revenue surprises of +10.14% and +3.33%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=622fd2c997dcc3e91196a3e661182616f1e1c5b485cb1ce6b6aaaf14463bb431"
    }
  },
  {
    "ts": null,
    "headline": "10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)",
    "summary": "Discover top large-cap value stocks using YCharts & Ben Graham Formula. Find high-yield dividend picks for October 2024.",
    "url": "https://finnhub.io/api/news?id=152912af2c4a5df828f99db4b1d1d51ec3df8c40a3ebf45b674b1a6cd3ae9f7d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761825089,
      "headline": "10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)",
      "id": 137267929,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1138851310/image_1138851310.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover top large-cap value stocks using YCharts & Ben Graham Formula. Find high-yield dividend picks for October 2024.",
      "url": "https://finnhub.io/api/news?id=152912af2c4a5df828f99db4b1d1d51ec3df8c40a3ebf45b674b1a6cd3ae9f7d"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb ups annual outlook as Q3 print exceeds estimates",
    "summary": "Investing.com -- Bristol-Myers Squibb lifted its full-year outlook slightly after reporting third-quarter earnings and revenue that beat market expectations.",
    "url": "https://finnhub.io/api/news?id=567b9d254f1991a884821027d7531f70902b37ea60366f2c9a8c3739a38c9aaf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761824300,
      "headline": "Bristol-Myers Squibb ups annual outlook as Q3 print exceeds estimates",
      "id": 137266782,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Investing.com -- Bristol-Myers Squibb lifted its full-year outlook slightly after reporting third-quarter earnings and revenue that beat market expectations.",
      "url": "https://finnhub.io/api/news?id=567b9d254f1991a884821027d7531f70902b37ea60366f2c9a8c3739a38c9aaf"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.",
    "summary": "Bristol Myers Squibb  hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio.  The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion.  Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.",
    "url": "https://finnhub.io/api/news?id=110f0830813ac85201f26d77bc43a593a1a6c7ab03256a56326c24a669b16259",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761823920,
      "headline": "Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.",
      "id": 137266539,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb  hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio.  The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion.  Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.",
      "url": "https://finnhub.io/api/news?id=110f0830813ac85201f26d77bc43a593a1a6c7ab03256a56326c24a669b16259"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Profit Soars, Raises Revenue Guidance",
    "summary": "Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs.",
    "url": "https://finnhub.io/api/news?id=825bc9743a70311114ac09e9d2e0722f3bccf0b5ea02a54a73815e5e6a579796",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761822660,
      "headline": "Bristol Myers Squibb Profit Soars, Raises Revenue Guidance",
      "id": 137266784,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs.",
      "url": "https://finnhub.io/api/news?id=825bc9743a70311114ac09e9d2e0722f3bccf0b5ea02a54a73815e5e6a579796"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers: Q3 Earnings Snapshot",
    "summary": "PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported third-quarter earnings of $2.2 billion. On a per-share basis, the Princeton, New Jersey-based company said it had profit of $1.08. Earnings, adjusted for non-recurring costs, came to $1.63 per share.",
    "url": "https://finnhub.io/api/news?id=4a555a448ff039bbda412dcd49c6dd2e3ce0c4a177d25fc0484cad1dbbf71aef",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761822602,
      "headline": "Bristol Myers: Q3 Earnings Snapshot",
      "id": 137266785,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported third-quarter earnings of $2.2 billion. On a per-share basis, the Princeton, New Jersey-based company said it had profit of $1.08. Earnings, adjusted for non-recurring costs, came to $1.63 per share.",
      "url": "https://finnhub.io/api/news?id=4a555a448ff039bbda412dcd49c6dd2e3ce0c4a177d25fc0484cad1dbbf71aef"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Reports Third Quarter Financial Results for 2025",
    "summary": "PRINCETON, N.J., October 30, 2025--Bristol Myers Squibb Reports Third Quarter Financial Results for 2025",
    "url": "https://finnhub.io/api/news?id=4065e40ec702f565b684eddb6d4adaab989c9c093e1c0aa14b5ab6062c76c9d2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761821940,
      "headline": "Bristol Myers Squibb Reports Third Quarter Financial Results for 2025",
      "id": 137266786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., October 30, 2025--Bristol Myers Squibb Reports Third Quarter Financial Results for 2025",
      "url": "https://finnhub.io/api/news?id=4065e40ec702f565b684eddb6d4adaab989c9c093e1c0aa14b5ab6062c76c9d2"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge",
    "summary": "Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on MRK stock.",
    "url": "https://finnhub.io/api/news?id=781901023f2d2f6d302e52852d90fc1f00f9272f1f80893967bd0459c3622dc9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761816041,
      "headline": "Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge",
      "id": 137266210,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389349379/image_1389349379.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on MRK stock.",
      "url": "https://finnhub.io/api/news?id=781901023f2d2f6d302e52852d90fc1f00f9272f1f80893967bd0459c3622dc9"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb Company 2025 Q3 - Results - Earnings Call Presentation",
    "summary": "2025-10-30. The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2025 Q3 earnings call.",
    "url": "https://finnhub.io/api/news?id=5ac264dd91b5d544846461483eefba3a1aa1c3f6f367ab0b8e34963a8e8e12f7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761813047,
      "headline": "Bristol-Myers Squibb Company 2025 Q3 - Results - Earnings Call Presentation",
      "id": 137266035,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "2025-10-30. The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2025 Q3 earnings call.",
      "url": "https://finnhub.io/api/news?id=5ac264dd91b5d544846461483eefba3a1aa1c3f6f367ab0b8e34963a8e8e12f7"
    }
  }
]